Injectable Drug Delivery Devices are defined as administration of a drug into patient’s blood through a delivery device. GlobalData's Medical Devices sector report, “Injectable Drug Delivery Devices – Medical Devices Pipeline Assessment, 2019" provides comprehensive information about the Injectable Drug Delivery Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
The Injectable Drug Delivery Devices Pipeline Assessment report provides key information and data related to:
Extensive coverage of the Injectable Drug Delivery Devices under development
Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates
Reviews of major players involved in the pipeline product development.
Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Injectable Drug Delivery Devices pipeline products.
Review of Recent Developments in the segment / industry
The Injectable Drug Delivery Devices Pipeline Assessment report enables you to:
Access significant competitor information, analysis, and insights to improve your R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Injectable Drug Delivery Devices under development
Formulate market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
The GlobalData Differentiation
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:
• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2009 and forecast to 2023
• 4,500+ industry-leading analysis and procedure reports covering growing sectors, market trends, investment opportunities and competitive landscape
• 56,000+ medical equipment company profiles
• 4,300+ company profiles of medical equipment manufacturers in China and India
• 2,000+ company profiles of medical equipment manufacturers in Japan
• 825+ companies’ revenue splits and market shares
• 1,900+ quarterly and annual medical equipment company financials
• 940+ medical equipment company SWOTs
• 21,500+ pipeline product profiles
• 34,500+ marketed product profiles
• 36,000+ clinical trials
• 36,500+ trial investigators
• 5,400+ reports on companies with products in development
• 33,000+ deals in the medical equipment industry
• 1,300+ surgical and diagnostic procedures by therapy area
• 50+ key healthcare indicators by country
For more information or to receive a free demonstration of the service, please visit:
https://medical.globaldata.com/home.aspx
Custom Requirements
Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.
Scope
– Extensive coverage of the Injectable Drug Delivery Devices under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Injectable Drug Delivery Devices and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry
Reasons to buy
The report enables you to:
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Injectable Drug Delivery Devices under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date
'
1 Table of Contents 2
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 24
2.1 Injectable Drug Delivery Devices Overview 24
3 Products under Development 25
3.1 Injectable Drug Delivery Devices – Pipeline Products by Stage of Development 25
3.2 Injectable Drug Delivery Devices – Pipeline Products by Segment 26
3.3 Injectable Drug Delivery Devices – Pipeline Products by Territory 27
3.4 Injectable Drug Delivery Devices – Pipeline Products by Regulatory Path 28
3.5 Injectable Drug Delivery Devices – Pipeline Products by Estimated Approval Date 29
3.6 Injectable Drug Delivery Devices – Ongoing Clinical Trials 30
4 Injectable Drug Delivery Devices – Pipeline Products under Development by Companies 31
4.1 Injectable Drug Delivery Devices Companies – Pipeline Products by Stage of Development 31
4.2 Injectable Drug Delivery Devices – Pipeline Products by Stage of Development 35
5 Injectable Drug Delivery Devices Companies and Product Overview 39
5.1 AdrenaCard, Inc. Company Overview 39
5.1.1 AdrenaCard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
5.2 Allergan Plc Company Overview 40
5.2.1 Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview 40
5.3 Alsensa ApS Company Overview 41
5.3.1 Alsensa ApS Pipeline Products & Ongoing Clinical Trials Overview 41
5.4 Antares Pharma Inc Company Overview 42
5.4.1 Antares Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 42
5.5 Aquavit Pharmaceuticals Inc Company Overview 44
5.5.1 Aquavit Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.6 Artemes Technologies, Inc. Company Overview 45
5.6.1 Artemes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
5.7 Ascendis Pharma A/S Company Overview 46
5.7.1 Ascendis Pharma A/S Pipeline Products & Ongoing Clinical Trials Overview 46
5.8 Ascil Proyectos SL Company Overview 49
5.8.1 Ascil Proyectos SL Pipeline Products & Ongoing Clinical Trials Overview 49
5.9 ASIS Corp Company Overview 52
5.9.1 ASIS Corp Pipeline Products & Ongoing Clinical Trials Overview 52
5.10 AzureBio SL Company Overview 55
5.10.1 AzureBio SL Pipeline Products & Ongoing Clinical Trials Overview 55
5.11 BCWorld Pharm Co Ltd Company Overview 56
5.11.1 BCWorld Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
5.12 Becton Dickinson and Co Company Overview 57
5.12.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 57
5.13 Bespak Europe Ltd Company Overview 60
5.13.1 Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
5.14 BioCorRx Inc Company Overview 62
5.14.1 BioCorRx Inc Pipeline Products & Ongoing Clinical Trials Overview 62
5.15 BioMarin Pharmaceutical Inc Company Overview 64
5.15.1 BioMarin Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 64
5.16 BioRestorative Therapies Inc Company Overview 65
5.16.1 BioRestorative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview 65
5.17 Bioxis Pharmaceuticals Company Overview 66
5.17.1 Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 66
5.18 Brigham and Women's Hospital Company Overview 67
5.18.1 Brigham and Women's Hospital Pipeline Products & Ongoing Clinical Trials Overview 67
5.19 Burke Pharmaceuticals LLC Company Overview 68
5.19.1 Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 68
5.20 Callisyn Biomedical Inc Company Overview 69
5.20.1 Callisyn Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 69
5.21 Cambridge Consultants Ltd Company Overview 70
5.21.1 Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview 70
5.22 Camurus AB Company Overview 71
5.22.1 Camurus AB Pipeline Products & Ongoing Clinical Trials Overview 71
5.23 Case Western Reserve University Company Overview 72
5.23.1 Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview 72
5.24 Catalent Inc Company Overview 73
5.24.1 Catalent Inc Pipeline Products & Ongoing Clinical Trials Overview 73
5.25 Cincinnati Children's Hospital Medical Center Company Overview 74
5.25.1 Cincinnati Children's Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview 74
5.26 Clearside BioMedical Inc Company Overview 75
5.26.1 Clearside BioMedical Inc Pipeline Products & Ongoing Clinical Trials Overview 75
5.27 DALI Medical Devices Ltd. Company Overview 78
5.27.1 DALI Medical Devices Ltd. Pipeline Products & Ongoing Clinical Trials Overview 78
5.28 DelSite, Inc. (Inactive) Company Overview 81
5.28.1 DelSite, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 81
5.29 Drexel University Company Overview 82
5.29.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview 82
5.30 Elcam Medical Company Overview 83
5.30.1 Elcam Medical Pipeline Products & Ongoing Clinical Trials Overview 83
5.31 EmboMedics Inc Company Overview 88
5.31.1 EmboMedics Inc Pipeline Products & Ongoing Clinical Trials Overview 88
5.32 Emergent BioSolutions Inc Company Overview 90
5.32.1 Emergent BioSolutions Inc Pipeline Products & Ongoing Clinical Trials Overview 90
5.33 EP Global Communications Inc (Inactive) Company Overview 93
5.33.1 EP Global Communications Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 93
5.34 EP Technologies LLC Company Overview 94
5.34.1 EP Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 94
5.35 Eveon SAS Company Overview 95
5.35.1 Eveon SAS Pipeline Products & Ongoing Clinical Trials Overview 95
5.36 EyePoint Pharmaceuticals Inc Company Overview 97
5.36.1 EyePoint Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 97
5.37 FHC Inc Company Overview 102
5.37.1 FHC Inc Pipeline Products & Ongoing Clinical Trials Overview 102
5.38 GeneSYS-ID Inc Company Overview 103
5.38.1 GeneSYS-ID Inc Pipeline Products & Ongoing Clinical Trials Overview 103
5.39 Ghent University Company Overview 104
5.39.1 Ghent University Pipeline Products & Ongoing Clinical Trials Overview 104
5.40 Globe Medical Tech Inc (Inactive) Company Overview 105
5.40.1 Globe Medical Tech Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 105
5.41 Inovio Pharmaceuticals Inc Company Overview 107
5.41.1 Inovio Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 107
5.42 InVivo Therapeutics Corp Company Overview 110
5.42.1 InVivo Therapeutics Corp Pipeline Products & Ongoing Clinical Trials Overview 110
5.43 Ipsen SA Company Overview 111
5.43.1 Ipsen SA Pipeline Products & Ongoing Clinical Trials Overview 111
5.44 JCR Pharmaceuticals Co Ltd Company Overview 112
5.44.1 JCR Pharmaceuticals Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 112
5.45 Lohmann Therapie-Systeme AG Company Overview 113
5.45.1 Lohmann Therapie-Systeme AG Pipeline Products & Ongoing Clinical Trials Overview 113
5.46 LyoGo Company Overview 114
5.46.1 LyoGo Pipeline Products & Ongoing Clinical Trials Overview 114
6.350 May 18, 2018: CR Announces Completion of PMDA Review of Clinical Trial Plan for Expanded Indication of GROWJECT for Short Stature Homeobox-containing Gene (SHOX) Deficiency-Phase 3 clinical trial to commence in July 2018 579
6.351 May 18, 2018: AstraZeneca: Q1 2018 Results 579
6.352 May 18, 2018: West Introduces New Analytical Services Capabilities 581
6.353 May 17, 2018: Albireo Provides First Quarter 2018 Business Update 582
6.354 May 17, 2018: Catalent Completes $5.5 Million Phased Clinical Storage Expansion At Kansas City Campus 582
6.355 May 16, 2018: EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S. 583
6.356 May 15, 2018: NEMERA Showcases at FCE Pharma 584
6.357 May 15, 2018: MRI Interventions Announces First Quarter 2018 Results 585
6.358 May 15, 2018: Milestone Scientific Provides Business Update for the First Quarter of 2018 587
6.359 May 14, 2018: Milestone Scientific Announces CompuFlo Epidural System Sales Strategy for the U.S.; Enters Agreement with Leading Distributor Covering Key Midwestern Territories 588
6.360 May 14, 2018: Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine 588
6.361 May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 589
6.362 May 10, 2018: Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update 591
6.363 May 10, 2018: Halozyme Reports First Quarter 2018 Results 592
6.364 May 10, 2018: Delcath Announces First Quarter 2018 Financial Results 593
6.365 May 09, 2018: Mylan Statement on Supply of EpiPen (epinephrine injection, USP) Auto-Injectors from Meridian Medical Technologies, a Pfizer company 595
6.366 May 09, 2018: Recipharm appoints new Chief Financial Officer 595
6.367 May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 596
6.368 May 09, 2018: Sanofi lays off 95 workers in Framingham 598
6.369 May 08, 2018: Sanofi Announces Appointment of Mr. Charles Billard as Chief Financial Officer and Key Managerial Personnel 598
6.370 May 08, 2018: Antares Pharma Reports First Quarter 2018 Operating and Financial Results 599
6.371 May 08, 2018: EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results 600
6.372 May 07, 2018: BioRestorative Therapies Appoints Wayne J. Olan as Clinical Director of Regenerative Disc/Spine Program 601
6.373 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 602
6.374 May 07, 2018: Milestone Scientific to Present at the 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and Reed Smith 603
6.375 May 03, 2018: BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance 603
6.376 May 03, 2018: Teva Reports First Quarter 2018 Financial Results 605
6.377 May 03, 2018: Emergent BioSolutions Reports First Quarter 2018 Financial Results 611
6.378 May 02, 2018: Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018 613
6.379 May 02, 2018: United Therapeutics Reports First Quarter 2018 Financial Results 614
6.380 May 01, 2018: Pfizer Reports First-Quarter 2018 Results 615
6.381 May 01, 2018: Catalent Reports Third Quarter Fiscal 2018 Results 620
7 Appendix 624
7.1 Methodology 624
7.2 About GlobalData 627
7.3 Contact Us 627
7.4 Disclaimer 627
